Combination therapy of BRAF inhibitors for advanced melanoma with <i>BRAF</i> V600 mutation: a systematic review and meta-analysis

Kim, Siin,Kim, Hyung Tae,Suh, Hae Sun Informa UK (Taylor Francis) 2018 The Journal of dermatological treatment Vol.29 No.3

Comparing the Efficacy of Leukotriene Receptor Antagonists and Intra-nasal Steroids in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis

Dami Lee,Siin Kim,Hae Sun Suh 대한약학회 2022 약학회지 Vol.66 No.1

We performed a systematic review and meta-analysis of randomized controlled trials to compare the efficacy of leukotriene receptor antagonists (LTRAs) and intranasal corticosteroids (INCSs) in patients with allergic rhinitis (AR). We searched OVID-MEDLINE (1946 to November 6, 2020), EMBASE, and the Cochrane Library databases for original articles. We used a random-effects model for the meta-analysis to determine the mean difference in the nasal symptom scores between the LTRA and INCS groups. Statistical heterogeneity was assessed using the I2 statistic and chi-squared test. A subgroup analysis was performed using the sample size, treatment duration, and comorbidities. We performed a database search on November 6, 2020, which yielded 922 reports. Of these, five studies were included in the metaanalysis. INCS treatment was more effective than LTRA treatment in relieving the nasal symptom of patients with AR (weighted mean difference [WMD] of the total nasal symptom score change=10.77, 95% confidence interval [CI]: 5.41 to 16.12). The results showed moderate heterogeneity (I2=33%, P=0.20). In the subgroup analysis, the results were homogenous, although some showed heterogeneity and some of the differences between the treatments were not statistically significant. There was moderate heterogeneity in the subgroup analysis (I2=63%, P=0.07), owing to the small sample size (n<600). The results of the study with a long treatment duration (more than 15 days) and those of the studies including patients with asthma were that the difference in the efficacy of INCS treatment and that of LTRA treatment was not statistically significant (WMD=3.86, 95% CI: −5.8 to 13.52; and WMD=8.18, 95% CI: −0.29 to 16.65, respectively). Although some of the subgroups showed heterogeneity and did not demonstrate statistically significant differences between the two treatments, the subgroup analysis consistently showed the superiority of INCS in treating patients with AR.

High electroluminescence efficiency and long device lifetime of a fluorescent green-light emitter using aggregation-induced emission

Hyocheol Jung,Hwangyu Shin,Siin Kim,Joonghan Kim,Byeong-Kwan An,Jihoon Lee,Hyotcherl Ihee,Jongwook Park 한국공업화학회 2020 Journal of Industrial and Engineering Chemistry Vol.87 No.-

Three bipolar materials, 4-(4,6-diphenyl-1,3,5-triazin-2-yl)-N,N-diphenylaniline (DPAT-Ph), 4-(4,6-diphenyl-1,3,5-triazin-2-yl)-N,N-diphenylnaphthalen-1-amine (DPAT-Na), and 10-(4,6-diphenyl-1,3,5-triazin-2-yl)-N,N-diphenylanthracen-9-amine (DPAT-An), were designed and synthesized. Toachieve a bipolar character, diphenylamine (DPA) moiety and 2,4-diphenyl-1,3,5-triazine (DPT) moietywere introduced as electron donating and electron accepting groups, respectively. The three compoundsexhibited UV maximum wavelengths (UVmax) at 395–454 nm and photoluminescence maximumwavelengths (PLmax) at 472–546 nm. 10-(4,6-Diphenyl-1,3,5-triazin-2-yl)-N,N-diphenylanthracen-9-amine (DPAT-An) shows AIE phenomenon even though DPAT-An does not have tetraphenylethylene(TPE) moiety which is representative AIE structure. DPAT-An exhibits over EQE value of 5% and longdevice lifetime of 1310 h without sublimation process.

The Current State and Prospects for Fully Inclusive Education

Chun Sik Min,Nam Siin Kim BK21 Project Force of Special Education Deagu Univ 2001 Journal of Asia-Pacific Special Education Vol.1 No.3

Recent fully inclusive education accepts the criticism and pursues a fully inclusive education environment where students with disabilities and non-disabled students learn and set together in their community. In genral, what should be of fully inclusive education in discussed in the following aspects: Frist, ti fits the assurance of fundamental human rights and social justice pursued bu most countries. Second, education is natural in terms of a constitution that is based on equity and the integration of curriculum for school education is naturally pursued for social intergration and proper education. Third, it complements a society is given on the integration of the isolated. Fourth. it is natural as a historically changing process.

노인 류마티스 관절염 환자에서의 요양급여심사기준 변경에 따른 TNF-α 억제제 약물사용양상

윤진영 ( Jinyoung Youn ),김시인 ( Siin Kim ),서혜선 ( Hae Sun Suh ) 한국보건경제정책학회(구 한국보건경제학회) 2016 보건경제와 정책연구 Vol.22 No.4

2014년 1월부터 류마티스 관절염 환자의 TNF-α 억제제 사용에 관한 급여기준이 기존의 다양한 검사 결과를 요구하는 방법에서 DAS28이라는 지표를 활용하는 방향으로 완화되었다. 본 연구에서는 이 급여기준의 변경 전후 1년간 류마티스 관절염(한국표준질병사인분류 M05, M06)노인 환자들의 TNF-α 억제제 이용 변화를 분석비교하였다. 건강보험심사평가원의 2013, 2014년 고령환자데이터셋을 활용하여 분석하였고, 구간별 회귀분석을 이용한 개입 시계열 분석방법을 적용하여 급여기준의 변경 전후 1년간 월별 TNF-α 억제제의 처방건과 사용량을 분석하였다. 사용량은 천명의 류마티스 관절염 환자의 일당 정립 용량(Daily Defined Dose)를 사용하였다. 분석결과, 급여기준 변경 후 월별 TNF-α 억제제의 처방건과 사용량은 유의한 변화를 보이지 않았다. 그러나 의료기관 종별에 따라 하위분석을 실시한 결과, 급여기준 변경 후 상급종합병원에서의 월별 처방과 사용량은 증가하였고, 종합병원, 병원/의원에서의 월별 처방과 사용량은 감소한 것으로 나타났다. 전체적으로 급여기준의 변경이 TNF-α 억제제의 처방과 사용에 영향을 미치지 않은 것으로 나타났으나 의료기관 종별에 따라 유의한 변화가 있었다. 급여기준의 개선으로 인해 장기간으로 보았을 때 류마티스 관절염 환자들의 TNF-α 억제제에 대한 접근성이 증가했는지에 대한 추가적인 연구가 필요할 것으로 보인다. In January 2014, there was a change in the reimbursement criteria of TNF-α inhibitor (TNFi) for RA patients. The new reimbursement criteria require DAS28 of a patient to assess disease activity, while previous reimbursement criteria required laboratory data and several subjective assessments. We examined the effect of a change in reimbursement criteria on the utilization of TNFi in RA patients. Data sources were 2013-2014 Aged Patient Sample data of Health Insurance Review and Assessment. Monthly trends in prescription and consumption of TNFi were estimated using segmented regression of interrupted time series. The consumption of TNFi was measured in terms of Daily Defined Dose per 1,000 RA patients per day. Subgroup analysis was conducted by the types of institution. There were increased baseline trends in prescription and consumption of TNFi, which were not significant. In subgroup analysis, tertiary hospital showed a significant increase in prescription and consumption immediately after the change in reimbursement criteria, while general hospital, hospital, and clinic showed a significant decrease in prescription and consumption. These trends were consistent throughout one year after the change in reimbursement criteria. This study shows that the change in reimbursement criteria of TNFi in RA patients had little impact on the overall utilization of TNFi. However, the change in reimbursement criteria significantly affected the pattern of TNFi utilization by the types of institution. Further research is needed to examine whether this change improved the accessibility to TNFi in RA patients.

파킨슨병 환자에서 위장관 운동조절제의 사용현황 및 처방에 미치는 요인

이창훈(Chang Hoon Lee),김시인(Siin Kim),서혜선(Hae Sun Suh) 대한약학회 2019 약학회지 Vol.63 No.6

Gastrointestinal motility drugs have been prescribed to manage functional dyspepsia in Parkinson’s disease (PD). However, anti-dopaminergic gastrointestinal motility drugs can exacerbate motor symptoms of PD. This study investigated the current use and factors affecting prescription of gastrointestinal motility drugs in PD patients. This retrospective cohort study extracted 3 patient groups (high-risk anti-dopaminergic drugs, low-risk anti-dopaminergic drugs and trimebutine group), by using the National Health Insurance Service-National Sample Cohort database. The most frequently prescribed drug was domperidone (n=437). Age and Charlson comorbidity index (CCI) were significantly different across three patient groups (p-value<0.05). Post hoc test (Tukey test) showed that high-risk group and trimebutine group were significantly different in age and CCI (p-value<0.05). The chi-square test for types of institution and clinical departments were significantly different across patient groups (p-value<0.001). Compared to tertiary hospital, general hospital [odds ratio (OR): 2.05, confidence interval (CI): 1.07-3.93], hospital/psychiatric hospital (OR: 4.28 CI: 2.11-8.65), and clinic (OR: 4.94 CI: 2.64-9.26) were more likely to prescribe high-risk drugs than low-risk drugs. Among clinical departments, neurology (OR: 0.08 CI: 0.05-0.14) was less likely to prescribe high-risk drugs than low-risk drugs. When comparing low-risk drugs group and trimebutine group, low-risk drugs were less likely to be prescribed in general hospital (OR: 0.40 CI: 0.18-0.92), hospital/psychiatric hospital (OR: 0.24 CI: 0.10-0.58), and clinic (OR: 0.16 CI: 0.08-0.36) than in tertiary hospital; Neurology (OR: 20.38 CI: 9.65-43.06) was more likely to prescribe low-risk drugs. Consequently, tertiary hospital and neurology were more likely to prescribe low-risk drugs than clinics and internal medicine, respectively.